[go: up one dir, main page]

AU2868200A - Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo - Google Patents

Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo

Info

Publication number
AU2868200A
AU2868200A AU28682/00A AU2868200A AU2868200A AU 2868200 A AU2868200 A AU 2868200A AU 28682/00 A AU28682/00 A AU 28682/00A AU 2868200 A AU2868200 A AU 2868200A AU 2868200 A AU2868200 A AU 2868200A
Authority
AU
Australia
Prior art keywords
efficacy
vivo
electrically
dna vaccine
vaccine immunity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU28682/00A
Inventor
Cheryl Goldbeck
Margaret A. Liu
Terry Pertile
Mark Selby
Jeffery Ulmer
Robert Walsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
eMed Corp
Original Assignee
Chiron Corp
eMed Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, eMed Corp filed Critical Chiron Corp
Publication of AU2868200A publication Critical patent/AU2868200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0412—Specially adapted for transcutaneous electroporation, e.g. including drug reservoirs
    • A61N1/0416—Anode and cathode
    • A61N1/0424—Shape of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/0404—Electrodes for external use
    • A61N1/0408—Use-related aspects
    • A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • A61N1/0432—Anode and cathode
    • A61N1/044—Shape of the electrode
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A61N1/303—Constructional details
    • A61N1/306—Arrangements where at least part of the apparatus is introduced into the body
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU28682/00A 1999-02-08 2000-02-07 Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo Abandoned AU2868200A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11899699P 1999-02-08 1999-02-08
US60118996 1999-02-08
US12918999P 1999-04-14 1999-04-14
US60129189 1999-04-14
PCT/US2000/002831 WO2000045823A1 (en) 1999-02-08 2000-02-07 Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo

Publications (1)

Publication Number Publication Date
AU2868200A true AU2868200A (en) 2000-08-25

Family

ID=26816956

Family Applications (1)

Application Number Title Priority Date Filing Date
AU28682/00A Abandoned AU2868200A (en) 1999-02-08 2000-02-07 Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo

Country Status (4)

Country Link
EP (1) EP1148885A4 (en)
AU (1) AU2868200A (en)
CA (1) CA2361601A1 (en)
WO (1) WO2000045823A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
ES2411096T3 (en) 1999-10-27 2013-07-04 Novartis Vaccines And Diagnostics, Inc. Activation of specific T lymphocytes against HCV
AU2002360648B2 (en) * 2001-12-14 2009-01-08 Genetronics, Inc. Methods for particle-assisted polynucleotide immunization using a pulsed electric field
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
AR038744A1 (en) * 2002-03-07 2005-01-26 Advisys Inc ELECTRODE ASSEMBLY FOR CONSTANT CURRENT ELECTROPORATION AND ITS USE
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US20060135906A1 (en) * 2004-11-16 2006-06-22 Akihiko Matsumura Iontophoretic device and method for administering immune response-enhancing agents and compositions
WO2006130581A2 (en) 2005-05-31 2006-12-07 Avigen, Inc. Methods for delivering genes
JP5215865B2 (en) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド Norovirus and sapovirus antigens
CA2668649A1 (en) * 2006-11-17 2008-05-29 Genetronics, Inc. Methods of enhancing immune response using electroporation-assisted vaccination and boosting
US8586055B2 (en) 2007-01-12 2013-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA immunization protocols
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
EP2234624B1 (en) * 2008-01-11 2018-06-20 Inovio Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
WO2012106281A2 (en) 2011-01-31 2012-08-09 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
EP2968606B1 (en) 2013-03-15 2020-10-07 Loma Linda University Treatment of autoimmune diseases
EP3848044A1 (en) 2013-05-21 2021-07-14 President and Fellows of Harvard College Engineered heme-binding compositions and uses thereof
US20180112006A1 (en) 2015-04-17 2018-04-26 The General Hospital Corporation Agents, systems and methods for treating cancer
AU2019396834A1 (en) 2018-12-13 2021-06-24 Newsouth Innovations Pty Limited Method and system for controlling molecular electrotransfer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5749847A (en) * 1988-01-21 1998-05-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
EP0438078B1 (en) * 1990-01-15 1996-06-05 Cino Rossi Iontophoresis device
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5830877A (en) * 1993-08-26 1998-11-03 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory
US5786464C1 (en) * 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
EP1023107B1 (en) * 1997-04-03 2006-08-30 Electrofect AS. Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
PL337584A1 (en) * 1997-06-30 2000-08-28 Rhone Poulenc Rorer Sa Improved method of transferring nucleic acid to eucariotic cells of multiple-cell organisms and connection enabling accomplishment of this method
CN1261812A (en) * 1997-06-30 2000-08-02 罗纳-布朗克罗莱尔股份有限公司 Device for the in vivo optimal electrotransfer of nucleic acid vectors into tissue
EP0932427A1 (en) * 1997-07-22 1999-08-04 Emed Corporation Needle for iontophoretic delivery of agent
WO1999036563A1 (en) * 1998-01-14 1999-07-22 Emed Corporation Electrically mediated cellular expression

Also Published As

Publication number Publication date
CA2361601A1 (en) 2000-08-10
WO2000045823A1 (en) 2000-08-10
WO2000045823A9 (en) 2001-10-11
EP1148885A1 (en) 2001-10-31
EP1148885A4 (en) 2002-05-08

Similar Documents

Publication Publication Date Title
AU2868200A (en) Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
AU1166502A (en) Human ect2 and methods of use
AU2001275177A1 (en) Cardiac disease treatment and device
AU2001253565A1 (en) Cardiac disease treatment and device
AU2001275176A1 (en) Cardiac disease treatment and device
AU2001281369A1 (en) Cardiac disease treatment and device
AU2001233296A1 (en) Establishing and maintaining therapeutic hypothermia
AUPQ155799A0 (en) Therapeutic methods and uses
AU2300001A (en) Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
AU7316800A (en) Physical strength enhancing agents and glycogen accumulation promoting agents
IL144845A0 (en) Vaccines and gene therapy compositions and methods of making and using the same
AU2001261375A1 (en) Human caspase-12 materials and methods
AU2002224471A1 (en) In vivo stimulation of angiogenic activity
AU3501700A (en) Human endokine alpha and methods of use
IL131719A0 (en) Iren protein its preparation and use
AU2001284380A1 (en) Therapeutic and cosmetic uses of heparanases
AU2001268053A1 (en) Human sparc-homologous (hsparc-h1) gene and methods and uses thereof
AU2001287269A1 (en) Human genes and expression products
AU2001267177A1 (en) Diagnosis and treatment of herpes infections
AU2001231141A1 (en) Novel human septin and uses thereof
EP1210111A4 (en) Gamma-herpesvirus dna and methods of use
HUP0201800A2 (en) Novel calpains and their use
AU2001269106A1 (en) Novel alpha expressed in heart and testis
AU5309500A (en) Novel human genes and proteins encoded thereby
GB0015371D0 (en) Tumour-cell specific gene expression and its use in cancer therapy

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase